Oculis is a global biopharmaceutical company (NASDAQ: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
- Mar 8 - Mar 9, 2023 BioCapital Europe
- Feb 23, 2023 from 5:54 PM to 6:00 PM UTC+8 The 38th Asia-Pacific Academy of Ophthalmology Congress - APAO
- Feb 3, 2023 from 10:45 AM to 11:55 AM PST Glaucoma 360 New Horizons Forum